New trial aims to boost survival in kids with rare lymphoma
NCT ID NCT05681260
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study compares two different ways of giving methotrexate (a chemotherapy drug) to children and teens newly diagnosed with T-cell lymphoblastic lymphoma, a rare cancer of the immune system. About 200 participants will be randomly assigned to one of two treatment plans to see which leads to better event-free survival. The goal is to find the most effective approach with fewer side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for T-CELL LYMPHOBLASTIC LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Shanghai Children's Medical Center
RECRUITINGShanghai, Shanghai Municipality, 200127, China
-
West China Second University Hospital
NOT_YET_RECRUITINGChengdu, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Experimental CAR-T therapy targets tough childhood blood cancers
- Promising combo for tough leukemia stalls: trial ends early
- New hope for tough leukemia: capivasertib combo enters human trials
- Engineered immune cells take on tough childhood cancers
- Texting to beat leukemia: study tests if phone reminders boost chemo adherence
- Engineered immune cells take on tough T-Cell cancers